Cisplatin/Tegafur/Uracil/Irinotecan Triple Combination Therapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma: A Phase I/II Clinical Study

LESSONS LEARNED: Cisplatin/tegafur/uracil/irinotecan triple combination therapy shows moderate response, especially in patients without previous chemoradiotherapy within the 6 months before this combination therapy. Toxicity is tolerable, and quality of life is improved in responders. BACKGROUND. Th...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, San-Chi, Chang, Peter Mu-Hsin, Yang, Muh-Hwa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AlphaMed Press 2016
Materias:
Clinical Trial Results
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4861372/
https://www.ncbi.nlm.nih.gov/pubmed/27091418
http://dx.doi.org/10.1634/theoncologist.2015-0515

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4861372/
https://www.ncbi.nlm.nih.gov/pubmed/27091418
http://dx.doi.org/10.1634/theoncologist.2015-0515

Ejemplares similares